Dear,

1. Disease-free survival and overall survival of patients with thyroid carcinoma were shown to be significantly decreased when glucose transporter 1 and tumoral monocarbonylate transporter 4 are expressed. https://journals.sagepub.com/doi/pdf/10.1177/1010428317695922 according to this, using GLUT1 inhibitors and MCT4 inhibitors may make sense.

Here I discussed GLUT1 inhibitors that are both available and accessible https://www.cancertreatmentsresearch.com/glucose-absorption-inhibitors-to-inhibit-tumor-growth/

Here I discussed MCT4 inhibitors that are both available and accessible https://www.cancertreatmentsresearch.com/ph-cancer-a-top-treatment-strategy/ Syrosingopine could be one of the best here https://www.cancertreatmentsresearch.com/community/metabolic-inhibitors/combo-metformin-and-syrosingopine-looks-awesome/#post-983

2. According to this https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5876306/ Metformin, DCA, 2DG, 3BP may help. Metformin and DCA are easy to access and use – oral treatments.

Indeed, Metformin may help given that intense cell progression and aggressive spread of the tumor occur in some patients, leading to loss of the ability to uptake iodine https://www.spandidos-publications.com/or/36/6/3673?text=fulltext while Metformin may help enhancement of iodide uptake via AMPK modulation https://www.ncbi.nlm.nih.gov/pubmed/23819433

Furthermore, addressing GLUT1 and MCT4 as well as using glycol inhibitors such as 2DG and a low sugar diet, will make thyroid cancer cells sensitive to Metformin https://www.ncbi.nlm.nih.gov/pubmed/26362676/

3. According to the above, I would consider using the following:

• Low Sugar/carbs diet
• Canagliflozin and Fenbendazole/Mebendazole as a GLUT1 inhibitor
• Syrosingopine as a MCT4 inhibitor
• Metformin as a AMPK modulator

Intravenous treatments that would work on the same line:

• 2DG metronomic to lower the available glucose and inhibit glycolisis https://www.cancertreatmentsresearch.com/a-new-approach-to-improve-effectiveness-of-cancer-therapies-is-getting-ready-to-begin-human-trials/
• High dose Vitamin C to inhibit glycolisis https://www.cancertreatmentsresearch.com/high-dose-vitamin-c-cancer/

This would be a minimum that I would use.

Kind regards,
Daniel

Other Relevant References:

Vitamin C kills thyroid cancer cells through ROS-dependent inhibition of MAPK/ERK and PI3K/AKT pathways via distinct mechanisms http://www.thno.org/v09p4461.htm

Tumor Therapy with Amanita phalloides: Remission of a Tumor Disease and Dietary Effect of Sugar http://omicsonline.org/tumor-therapy-with-amanita-phalloides-remission-of-a-tumor-disease-and-dietary-effect-of-sugar-2157-7013.1000147.pdf

Amplitude-modulated electromagnetic fields for the treatment of cancer: Discovery of tumor-specific frequencies and assessment of a novel therapeutic approach http://www.jeccr.com/content/28/1/51  

Purpose: Because in vitro studies suggest that low levels of electromagnetic fields may modify cancer cell growth, we hypothesized that systemic delivery of a combination of tumor-specific frequencies may have a therapeutic effect. We undertook this study to identify tumor-specific frequencies and test the feasibility of administering such frequencies to patients with advanced cancer.

Patients and methods: We examined patients with various types of cancer using a noninvasive biofeedback method to identify tumor-specific frequencies. We offered compassionate treatment to some patients with advanced cancer and limited therapeutic options.

Results: We examined a total of 163 patients with a diagnosis of cancer and identified a total of 1524 frequencies ranging from 0.1 Hz to 114 kHz. Most frequencies (57–92%) were specific for a single tumor type. Compassionate treatment with tumor-specific frequencies was offered to 28 patients. Three patients experienced grade 1 fatigue during or immediately after treatment. There were no NCI grade 2, 3 or 4 toxicities. Thirteen patients were evaluable for response. One patient with hormone-refractory breast cancer metastatic to the adrenal gland and bones had a complete response lasting 11 months. One patient with hormone-refractory breast cancer metastatic to liver and bones had a partial response lasting 13.5 months. Four patients had stable disease lasting for +34.1 months (thyroid cancer metastatic to lung), 5.1 months (non-small cell lung cancer), 4.1 months (pancreatic cancer metastatic to liver) and 4.0 months (leiomyosarcoma metastatic to liver).

Conclusion: Cancer-related frequencies appear to be tumor-specific and treatment with tumor-specific frequencies is feasible, well tolerated and may have biological efficacy in patients with advanced cancer.

Association between Circulating Fibroblast Growth Factor 21 and Aggressiveness in Thyroid Cancer. https://www.ncbi.nlm.nih.gov/pubmed/31408968 But FGFR inhibitor difficult to find – there are some oncology drugs approved for this but probably not accessible

The Insulin and IGF-I Pathway in Endocrine Glands Carcinogenesis http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3423951/#B213

Hello Daniel,

Thank you so much for taking time and helping with information.  Request to kindly help me with below

Once the course of these meds starts what is the duration of these meds to be taken OR can they be taken long term until the cancer is gone. 
Kindly suggest the Dosages to be taken per day  of : Metformin, Canagliflozin and Syrosingopine, will it be fine if  these meds taken with meal.
Will Ozone therapy also help

Kindly suggest 

Thank you so much for the help
Ravi

@ravi-teja

Dear Ravi,

You are very welcome. It is best that first you try to find the required doses yourself. After that you let me know what daily dose you think is best and I will give you my feedback.

Also, before you start with these drugs please make sure there is no danger of combining them with current drugs your brother may use at this point. So it is best to align with a medically trained person and also check drug interactions here https://reference.medscape.com/drug-interactionchecker?src=google

Kind regards,
Daniel

@daniel

Hello Daniel 

Thank you so much for the suggestion. It means a lot. 

I have been trying to fetch Syrosingopine locally in India but unable to find it in any medical outlet .

Is there any other alternative to Syrosingopine for  MCT4 inhibition which can be easily accessible.

Kindly suggest please.

Thanks

Ravi

@ravi-teja

Hi Ravi,

You are welcome. Not sure if Diclofenac can do similar job but this could be another MCT4 inhibitor https://www.cancertreatmentsresearch.com/community/metabolic-inhibitors/combo-metformin-and-diclofenac/#post-1118

Lipophilic statins such as Atorvastatin could be another option https://www.ncbi.nlm.nih.gov/pubmed/16621368 . But the concentration required to reach MCT4 inhibition may be much higher. So it is best to try to add other MCT4 inhibitors such as Quercetin to increase the chance of inhibiting MCT4. A few more MCT inhibitors were discussed here https://www.cancertreatmentsresearch.com/ph-cancer-a-top-treatment-strategy/

Kind regards,
Daniel

@daniel

Thank you, Daniel !

Good day, Daniel 

Thank you for the valuable information. It's really helpful.

Daniel, also will Loratadine also help in MCT4 inhibition. 

Kindly suggest.

Thanks

Ravi

@ravi-teja

Hi Ravi,

I have no info to suggest that Loratadine has an impact on MCT4.

Kind regards,
Daniel

@daniel

Hi Daniel

Thank you very much 

Have a good day ahead

Regards

Ravi

Hello Daniel - Good day

Another small query. My brother is loosing weight and muscle mass during this process. Can some one with cancer use Plant based protein powder to maintain muscle and weight. Also if using protein is there any offlabel drugs to be included to block protein to cancer cells . Please suggest. 

Thank you for your time 

Ravi

@ravi-teja

Hi Ravi, 

Protein powders it's not an area that I investigated. The best is to contact an expert in nutrition. It's also important to understand if the weight loss is due to the medication and the diet your brother is on, or due to the tumor. I do investigate the mechanisms behind the weight loss due to cancer and would like to write about it as soon as i get the time. Here is an article where I touched a little this subject https://www.cancertreatmentsresearch.com/addressing-gluconeogenesis/

Kind regards,
Daniel